Drugs / BAY3547922
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06345001 | Aug 2024 → Mar 2025 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06764316 Background | Feb 2025 → Jul 2029 expected | hepatocellular carcinoma | Bayer | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY3547922 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06345001 ↗ |
| Modality | Monoclonal antibody | “BAY 3547922, a Monoclonal Antibody-chelator Conjugate” NCT06345001 ↗ |
| Route | Intravenous | “IV, Single infusion” NCT06345001 ↗ |